注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Syros Pharmaceuticals Inc是一家生物制药公司。该公司致力于重新保护小分子控制基因表达的能力。该公司致力于开发单一基因突变导致的癌症和疾病的治疗方法,也称为单基因疾病,并建立基因控制医学的临床阶段管道。该公司的主要候选产品包括Tamibarotene、SY-2101和SY-5609。其他米蛋白是一种选择性维甲酸受体α(RARα),RAR激动剂阳性的高危骨髓增生异常综合征(HR-MDS)和急性髓系白血病(AML)患者。其SY-2101是一种口服形式的三氧化二砷(ATO),用于治疗急性早幼粒细胞白血病(APL)。其SY-5609是一种选择性和有效的口服细胞周期蛋白依赖性激酶7(CDK7)抑制剂,目前正在为某些实体瘤和血癌患者开发。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Peter Wirth | 71 | 2017 | Independent Chairman |
Nathanael S. Gray | - | 2013 | Scientific Founder & Member of Scientific Advisory Board |
Scott A. Biller | 67 | 2013 | Member of Scientific Advisory Board |
Stefan Knapp | - | 2013 | Member of Scientific Advisory Board |
Richard A. Young | 69 | 2011 | Scientific Founder, Member of Scientific Advisory Board & Director |
Chris Vakoc | - | 2013 | Member of Scientific Advisory Board |
Bradley E. Bernstein | - | - | Member of Scientific Advisory Board |
Mark Murcko | 63 | 2013 | Member of Scientific Advisory Board |
Robert A. Weinberg | - | 2013 | Member of Scientific Advisory Board |
Aviv Regev | 52 | 2013 | Member of Scientific Advisory Board |
Gerard Evan | - | 2013 | Member of Scientific Advisory Board |
Nancy A. Simonian | 62 | 2012 | Director |
Roger D. Tung | 63 | - | Member of Scientific Advisory Board |
Timothy C. Tyson | 70 | 2022 | Independent Director |
Conley Chee | 53 | 2021 | CEO, President & Director |
Marsha H. Fanucci | 69 | 2015 | Independent Director |
Srinivas Akkaraju | 55 | 2017 | Independent Director |
Andrew M. Oh | 52 | 2022 | Independent Director |
Sue Gail Eckhardt | 65 | 2020 | Independent Director |
Deborah Dunsire | 61 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核